You are here: Home » Companies » News
Business Standard

A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol

Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statins

Zydus Lifesciences | cholesterol

Vinay Umarji  |  Ahmedabad 

Cadila Healthcare changes name to Zydus Lifesciences Limited

For the first time in India, Ltd. (formerly Cadila Healthcare Ltd) has launched a new class of drug 'Bemdac' to treat uncontrolled low density lipoprotein (LDL-c).

With uncontrolled LDL-c posing a major risk of developing cardiovascular diseases, the same was lacking proper treatment despite patients' life-style modifications and use of maximum tolerated dose of statins. However, now addressing the pressing healthcare need, the oral drug Bemdac will offer a new line of treatment for patients from uncontrolled levels of LDL-c.

Often referred to as bad since it gets deposited in the walls of the blood vessels, LDL-c increases the chances of health problems such as heart attack or stroke.

Uncontrolled LDL-c currently leads to imbalance of lipids including cholesterol, LDL-c, triglycerides and high-density lipoprotein (HDL), commonly known as dyslipidemia. Citing various studies, on Friday stated that eight out of 10 Indians are dyslipidemic and 112 million adults suffer from high levels of LDL-c.

Moreover, seven out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c. Besides, 5.4 million Indians are found to be intolerant to statin therapy. However, Bemdac's Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins.

With Zydus already having several leading brands to address cardiac care and dyslipidemia including Atorva, Clopitorva, Zyrova and Pivasta, Bemdac is now an important addition to the company's portfolio of medicines for managing dyslipidemia and cholesterol, said Zydus Lifesciences' managing director Dr. Sharvil Patel.

For instance, the company’s brand Atorva is a leader in the Atorvastatin market with a market share of 18.4 per cent, ranking second in terms of market share in the Rs 2162 crore statin segment, based on AWACS Report of February 2022.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, May 13 2022. 18:39 IST